{"ticker": {"uuid": "fa5bae3f-e4e3-4489-b588-677c9a238584", "symbol": "MXCT", "name": "MaxCyte Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026", "summary": "MaxCyte, Inc. announced that it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are encouraged to register onli", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/maxcyte-to-report-second-quarter-2026-financial-results-on-august-12-2026/2385448/amp", "source_name": "The Manila Times", "published_at": "2026-07-16T04:07:00", "published_display": "16 Jul 2026 04:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte to report Q2 2026 financial results on August 12", "summary": "MaxCyte, Inc. is scheduled to release its second-quarter 2026 financial results after the U.S. market close on Wednesday, August 12, 2026. This will be followed by a conference call hosted by company management at 4:30 p.m. Eastern Time. Investors are required to register online ", "url": "https://scanx.trade/stock-market-news/companies/maxcyte-to-report-q2-2026-financial-results-on-august-12/45697293", "source_name": "scanx.trade", "published_at": "2026-07-15T21:39:49", "published_display": "15 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte will discuss second-quarter results on Aug. 12", "summary": "MaxCyte (NASDAQ: MXCT) announced it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. Following the release, company management will host an earnings conference call at 4:30 p.m. Eastern Time, which investors can ac", "url": "https://www.stocktitan.net/news/MXCT/max-cyte-to-report-second-quarter-2026-financial-results-on-august-mf6wmsoustfs.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:23", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of MaxCyte, Inc. \u2013 DUS:MYE0", "summary": "The article displays the enterprise value to revenue forward for MaxCyte, Inc. (DUS:MYE0) on the Dusseldorf Stock Exchange. It provides a financial overview of the company, indicating the market was closed with no trades recorded at the time of the report. The content appears to ", "url": "https://www.tradingview.com/symbols/DUS-MYE0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T13:39:02", "published_display": "12 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MaxCyte, Inc. \u2013 DUS:MYE0", "summary": "This article provides the \"Price to sales forward\" financial metric for MaxCyte, Inc. (DUS:MYE0) on the Dusseldorf Stock Exchange, as presented on the TradingView platform. It acknowledges that the market is currently closed with no trades. The content is primarily a data point w", "url": "https://www.tradingview.com/symbols/DUS-MYE0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T00:10:59", "published_display": "12 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte(MXCT) Stock Options Chain | Quotes & News", "summary": "This article provides details on the stock options chain for MaxCyte (MXCT). It also indicates that quotes and news related to MaxCyte are available.", "url": "https://www.moomoo.com/stock/MXCT-US/options-chain?chain_id=Name1K9-3FXPhg.1kvnlg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A61,%22invite%22%3A%2270107943%22,%22promote_content%22%3A%22mm%3Afeed%3A112092721905669%22,%22f%22%3A%22www.moomoo.com%2Fstock%2FCSCO-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T08:11:39", "published_display": "09 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MaxCyte, Inc. \u2013 DUS:MYE0", "summary": "This article displays the \"Price to earnings forward\" metric for MaxCyte, Inc. (DUS:MYE0) on TradingView. It appears to be a financial data point presented without further commentary or analysis, indicating market performance data. The content primarily consists of navigation and", "url": "https://www.tradingview.com/symbols/DUS-MYE0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T06:41:03", "published_display": "09 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc focuses on cell engineering. Nasdaq-listed MXCT targets long-term growth", "summary": "MaxCyte Inc, a Nasdaq-listed life sciences company, specializes in cell engineering platforms crucial for advanced therapeutics and research. The company aims for long-term growth by expanding its technology footprint as demand for cell and gene therapies increases globally. MaxC", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/maxcyte-inc-focuses-on-cell-engineering-nasdaq-listed-mxct-targets/69724187", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T13:39:15", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MaxCyte, Inc. \u2013 NASDAQ:MXCT", "summary": "This article provides the enterprise value to EBITDA forward for MaxCyte, Inc. (NASDAQ: MXCT). It appears to be a financial data snippet from TradingView, indicating the value and any changes for the specified financial metric. The content itself seems to be a display of this sin", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:09:03", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte stock leans on platform demand. Nasdaq listing stays central.", "summary": "MaxCyte Inc. (MXCT) is a Nasdaq-listed cell-engineering company whose investment case focuses on the adoption and usage of its Flow Electroporation platform by biopharma and research customers. Without new immediate catalysts, the company's performance is tied to execution, custo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/maxcyte-stock-leans-on-platform-demand-nasdaq-listing-stays-central/69680975", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:12:13", "published_display": "03 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of MaxCyte, Inc. \u2013 NASDAQ:MXCT", "summary": "This article provides a brief snapshot of the \"Price to book forward\" metric for MaxCyte, Inc. (NASDAQ:MXCT) on TradingView. It shows the period, value, and change percentages for this financial indicator. The content is concise and focused solely on this specific financial data ", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:09:40", "published_display": "29 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MaxCyte, Inc. \u2013 LS:A2AGVE", "summary": "This article provides access to the \"Price to sales forward\" financial metric for MaxCyte, Inc. (A2AGVE) on the TradingView platform. It highlights that market data is provided by ICE Data Services and FactSet, and SEC filings by Quartr. The content mainly consists of navigation ", "url": "https://www.tradingview.com/symbols/LS-A2AGVE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:40:55", "published_display": "29 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MXCT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for MaxCyte, Inc. (MXCT) stock, based on analyst ratings and current market data. It includes information on the company's past performance, stock volatility, market capitalization, earnings, revenue, and future outlook, as well a", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:33", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MYE0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MaxCyte, Inc. (MYE0) stock, including analyst price targets, past financial performance, and key company metrics. It details the stock's highest and lowest recorded prices, upcoming earnings reports, and financial statistics such as revenue, n", "url": "https://www.tradingview.com/symbols/DUS-MYE0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:59", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT)", "summary": "This article provides an overview of MaxCyte, Inc. (NASDAQ:MXCT) stock, including its current price, performance, and analyst forecasts. It covers financial data, market capitalization, earnings reports, and technical analysis, noting that MXCT's stock has shown recent gains but ", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:25", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating", "summary": "Craig-Hallum has reiterated its Buy rating on MaxCyte (MXCT.US). This indicates a continued positive outlook from the firm regarding the company's stock.", "url": "https://www.moomoo.com/news/post/72030663/craig-hallum-maintains-maxcyte-mxctus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-23T20:13:17", "published_display": "23 Jun 2026 20:13", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectorBuilder Partners With MaxCyte\u00ae to Advance Clinical-Grade Cell Engineering", "summary": "VectorBuilder and MaxCyte have formed a strategic partnership to create a new gene delivery solution for ex vivo cell engineering. This collaboration integrates VectorBuilder\u2019s MiniVec\u2122 plasmid system with MaxCyte\u2019s Flow Electroporation\u00ae technology, aiming to enhance cell viabili", "url": "https://www.businesswire.com/news/home/20260623060175/en/VectorBuilder-Partners-With-MaxCyte-to-Advance-Clinical-Grade-Cell-Engineering", "source_name": "Business Wire", "published_at": "2026-06-23T13:11:57", "published_display": "23 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) grants RSUs and stock options to director", "summary": "MaxCyte (MXCT) director John Joseph Johnston was granted 30,421 restricted stock units and stock options for 49,579 shares as part of his annual non-employee director compensation. The RSUs will vest on June 17, 2027, contingent on his continued service, and the stock options hav", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-fc8a30b7d649.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:09:25", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant", "summary": "MAXCYTE director Cynthia Collins was granted 30,421 restricted stock units and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. These equity awards, made on June 17, 2026, are part of the company's Equity Grant Policy for non-employee di", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-86da2d334293.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:09:25", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 MaxCyte Inc For: 22 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing update, specifically a Form 4 for MaxCyte Inc, dated June 22. It primarily serves as a notice of the filing without providing further details on the content of the form itself. The content primarily consists of market data an", "url": "https://za.investing.com/news/stock-market-news/form-4-maxcyte-inc-for-22-june-93CH-4338578", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T22:28:00", "published_display": "22 Jun 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director receives RSUs and options in annual equity grant", "summary": "MaxCyte Inc. director Stanley C. Erck received an annual equity grant comprising 30,421 restricted stock units (RSUs) and an option to purchase 49,579 shares at $1.13 per share. The RSUs will vest on June 17, 2027, contingent on his continued service. Following this grant, Erck's", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-2151fe79724b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:25", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award", "summary": "MAXCYTE (NASDAQ: MXCT) director Douglas Richard was granted 30,421 Restricted Stock Units (RSUs) and 49,579 stock options with an exercise price of $1.13 per share. These grants are part of the company's annual equity award policy for non-employee directors, with the RSUs vesting", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-60ccfe04342d.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant", "summary": "MaxCyte (MXCT) director Brooke William W was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share. The RSUs vest on June 17, 2027, contingent on his continuous service, and the stock options expir", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-a0a54f6d3fa7.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director receives RSU and stock option grant", "summary": "MaxCyte (MXCT) director Yasir B. Al-Wakeel was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares at an exercise price of $1.13 per share. These equity awards are part of his annual non-employee director compensation package, with the shares vesting ", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-de816ac43149.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director awarded RSUs and stock options in annual grant", "summary": "MaxCyte, Inc. director Rekha Hemrajani received an annual equity grant comprising 30,421 restricted stock units (RSUs) and 49,579 stock options with a strike price of $1.13, expiring in 2036. These awards, part of the non-employee director policy, vest on June 17, 2027, contingen", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-d140bab17f05.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVWdCVWkxMnc1WHRoYURZRzlQOWVuYkVFWjJqa01OOEI3SE5vaFcyR09iYXlFdGY5QzQweV9WVDJidUZDa2JQRlc2NG5yWC13OWo3YnUzV0tfVVVzQW91aE9lUkgwVkNpR3RBUDdhXzhPMmZyd2NLc3dMYkVhVVFIWHlsN0MxamNwOF9NRFVQZmJubnBhbENQWXFHb294UjdmQ1kyX0tjQUM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)", "summary": "Craig-Hallum analyst Matt Hewitt has reaffirmed a Buy rating on MaxCyte (MXCT). Despite recent negative insider sentiment, the company reported Q1 revenue of $9.65 million and a GAAP net loss of $4.75 million, with an analyst consensus of Moderate Buy and a price target of $4.00.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MXCT-Q/pressreleases/2551932/craig-hallum-reaffirms-their-buy-rating-on-maxcyte-mxct/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T10:39:23", "published_display": "19 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Stock - chart levels and volatility on a quiet news day", "summary": "MaxCyte stock traded on Nasdaq without new corporate headlines, leading analysts to focus on its chart performance, volatility, and key moving averages. The company, which develops cell-engineering technologies for biopharma partners, is in a period of consolidation. Investors ar", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/maxcyte-stock-chart-levels-and-volatility-on-a-quiet-news-day/69574749", "source_name": "AD HOC NEWS", "published_at": "2026-06-18T16:40:41", "published_display": "18 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte shareholders elect directors and approve auditor at annual meeting", "summary": "MaxCyte, Inc. announced the results of its 2026 annual meeting, where shareholders elected three Class II directors\u2014Patrick Balthrop, Cynthia Collins, and Stanley Erck\u2014and ratified CohnReznick LLP as its independent auditor for the fiscal year ending December 31, 2026. Despite th", "url": "https://www.investing.com/news/sec-filings/maxcyte-shareholders-elect-directors-and-approve-auditor-at-annual-meeting-93CH-4748661", "source_name": "Investing.com", "published_at": "2026-06-18T11:40:25", "published_display": "18 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com", "summary": "MaxCyte, Inc. held its 2026 annual meeting where shareholders elected three Class II directors\u2014Patrick Balthrop, Cynthia Collins, and Stanley Erck\u2014and ratified CohnReznick LLP as their independent auditor for the fiscal year ending December 31, 2026. Despite the stock being down ", "url": "https://ng.investing.com/news/sec-filings/maxcyte-shareholders-elect-directors-and-approve-auditor-at-annual-meeting-93CH-2564147", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T10:09:54", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc (MXCT) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE1wWV9odWNtOFdLODRVSWRQTzZzOFM4d2dwQWljNF9sWE9UdFVOTG85SVY5VS0ycWVsXzZQZFE0eWtvOXNoc3NDa08tb245WXJQQ1hTelFJVGhMUHJQdU5BTmVBdmlLeGh4N0lWQ1p5REw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:47:12+00:00", "published_display": "17 Jun 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MaxCyte Inc. (MXCT) Q1 2026 Earnings: EPS Surges Past Estimates Despite Revenue Disclosures Left Unclear - Annual Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxOX0lBMXRtQTh4QzZCUkwtRmEzbVRpc09uYW43MWNiR1ZTVHFQUC1TV2Z0dk40UTRBSHhxMWh4clRaQTA3bVVoNkR2WllkN2JmX1FLSDU1NHVDOFhaX0lVUy1xa0Z2RVZQS0lOODVRU0Q3bmR4bTEydHBSSkh2akRJYTF6YU9laDFtd0ktQ1EyMGRwdnlrZmRTYno0NzVyOWYwLWl4Z2FnNFZ1ZV9EYktMR2o4N3VmbG5FbUpzLXRRUmFUYi0xNHhiam5pOUNuQXoyVXU1NlJRZzdqUWs5ZDEzXzNn?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors", "summary": "", "url": "https://finance.yahoo.com/news/why-maxcyte-mxct-becoming-high-092702917.html", "source_name": "Insider Monkey", "published_at": "2026-05-13T09:27:02+00:00", "published_display": "13 May 2026 09:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...", "summary": "", "url": "https://finance.yahoo.com/news/maxcyte-inc-mxct-q1-2026-050148503.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:01:48+00:00", "published_display": "13 May 2026 05:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/042a4e49-e2c9-383d-8f68-731df522edbe/maxcyte-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-13T01:09:08+00:00", "published_display": "13 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/123ba984-df64-3ac7-8a5f-1121813da801/maxcyte%2C-inc.-q1-2026.html", "source_name": "Moby", "published_at": "2026-05-13T00:53:09+00:00", "published_display": "13 May 2026 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/news/maxcyte-inc-mxct-reports-q1-214004141.html", "source_name": "Zacks", "published_at": "2026-05-12T21:40:04+00:00", "published_display": "12 May 2026 21:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance", "summary": "", "url": "https://finance.yahoo.com/news/maxcyte-reports-first-quarter-2026-200500117.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte posts $4.8M loss, still lines up $10M stock buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRjZoYXE5MzlmY3VvWmJrcmdkMVl1OE1zX0M3b2c4cE95Nk1hZ043a2xOMWNnS3RxUUdpbFRBT05fdGxraFd4aVkweHpVcXExa3pBOFhRM2lhWEhxMlNob1ItZWRTbVlNeUFHZjM4WkNmcVZWVHExeFplNkRwOFNreFVhYlpNcVhuN1R0S0ljbmdPZENZTFZZeG55VDVyOFBtMkxtX2NXV2dUSGdsMjRWLV9rd3FNeVBjeXJYRlBCYno?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MaxCyte Inc. (MXCT) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNSGF3clA5MTNxXzFxYTBCN1l4cDNuNFRoMFlRdmFQaGZMUkVhSVdZanJaSHdPQ3UyR1Z1Z1RENUFERmVpWkdNaUZ2bUVNaTZCaXhUZ25pWmVrZ05WREFSdXdIT2xUdmgzU1VTdFRaM0hIc3c0MjRmekhGeW5jaXhSMlVxMHJrTHk2TnRTYnpOSW5ydw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPSzR3SU53LTZEU0hiMWtqMDBGM1pjWF9YSXpBNXNPYlZEZ3dTZlJ4OTJDOV90a0dGTHFQbGx5OU5QbzlpXzFDb3RhOXA0dXdjS04wVGdaa2lDVkUtdFNMcHQ3UWRZaEJZcHkxOU9HcjVMMVU0aG5Sc0k3NjUxZ0hITUJ0YmcxcjZ5TlFhX2ZYdUh5YnR1Tnk0?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New MaxCyte lab device runs 96 cell samples in a three-minute cycle", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPTXZXWFhIdnhfZzRpLXI2S1czLU1zcHVQQ0ZVVUJYNm5jaWNIa0liUHJGc0o2dnlNekhac3podTRGc0JjRFQwVmNENUtINmRmVF9oQzNhdWtYeTAxTWxjd2ZINVZfQ18zcVhMNFlLTmFvQlpTNU9Rdkoxai1nbWtJT3N6Z3JDZFZmMGw0cEtWN3V2NlFMNTVaRlJDdEZSTHZtejRnUGtRa3pQLUJKZzhidXIyVWFFV29lNVlORmI0MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPeTFtdkhCd0ZseE96MkkwM3lNd3RrN2xnd2R1Mmc4dG5TSDR1TDJSNjJ1VjFNQUU0WkUzTnZoMkUxVWl4UGJPdEFKUWs5a18tbnZzdWQteHlncXg0dlp2amdZMzFETE5xNWpIMW9tVWIweV8zLTgzaXFVX2RVdGVNdmtZQkdzWnJBWWhpTmppbjg5NHdtTWJFdElqREFyeWQtYkk5cGpKY1ZZRzJ3SVF2RXd2Yk5uVk9S?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy MaxCyte (MXCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1aUWQ3RzRHcDVRQTdYS3dWaVNUUkFPeWNpOU9CQWVMYXFSMF9jemdHT0xzbk4tMkNicmlkczA4Xy1LVUdnTER0N21jcUJMYURKcjhFYWwydTVlSkQzeWJFNHNUYmdnaHF3Z3NxUg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-08-01T15:54:32+00:00", "published_display": "01 Aug 2021 15:54", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SUNDAY NEWSPAPER SHARE TIPS: MaxCyte and IQE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcWdDZ29zR3FUUnR3alZsUG1uUk52eG80SEU0ZG80dDlaSFhfVWJ1NXlfcGg1eVV2aTczdFgyUTBjZTMyOG02V1d0aXhBbTJObjNmcmdmWTBYemlDOThfR1lOLU9xRE8tTTBfd1l2SkN1LWdmUkJxTWlVcWhmZXBJZmZDVHQwQlExRkEtcUR4LTVfS2NnX01ndmNFUlkzSUg3TlcwbEZ5OHBQZ9IBrwFBVV95cUxNMVlrdHZ5aDFiWC1BeHN4S25YLVFVdVo0ZXpsTHI4WDhNWDQ5N0EtWF85WlQ3SjcydEFuR2YxX2xndVFQM0tLeHhDUnFvVGJxUjdFYjZIMVcyZTY3NkF1Q3VXazZDVFNNVnZ0YVZaRmhSdEptRzlmc1FGcGk1WkhGd0d5OVh4SVI1Y01Nb05JcFRpdG1NMWhKWTMyZ0RXS191T0txZXVLcmRBcEVwYXdv?oc=5", "source_name": "This is Money", "published_at": "2019-05-26T07:00:00+00:00", "published_display": "26 May 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026", "summary": "MaxCyte, Inc. announced that it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are encouraged to register onli", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/maxcyte-to-report-second-quarter-2026-financial-results-on-august-12-2026/2385448/amp", "source_name": "The Manila Times", "published_at": "2026-07-16T04:07:00", "published_display": "16 Jul 2026 04:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte to report Q2 2026 financial results on August 12", "summary": "MaxCyte, Inc. is scheduled to release its second-quarter 2026 financial results after the U.S. market close on Wednesday, August 12, 2026. This will be followed by a conference call hosted by company management at 4:30 p.m. Eastern Time. Investors are required to register online ", "url": "https://scanx.trade/stock-market-news/companies/maxcyte-to-report-q2-2026-financial-results-on-august-12/45697293", "source_name": "scanx.trade", "published_at": "2026-07-15T21:39:49", "published_display": "15 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte will discuss second-quarter results on Aug. 12", "summary": "MaxCyte (NASDAQ: MXCT) announced it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. Following the release, company management will host an earnings conference call at 4:30 p.m. Eastern Time, which investors can ac", "url": "https://www.stocktitan.net/news/MXCT/max-cyte-to-report-second-quarter-2026-financial-results-on-august-mf6wmsoustfs.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:23", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MaxCyte, Inc. \u2013 DUS:MYE0", "summary": "The article displays the enterprise value to revenue forward for MaxCyte, Inc. (DUS:MYE0) on the Dusseldorf Stock Exchange. It provides a financial overview of the company, indicating the market was closed with no trades recorded at the time of the report. The content appears to ", "url": "https://www.tradingview.com/symbols/DUS-MYE0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T13:39:02", "published_display": "12 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MaxCyte, Inc. \u2013 DUS:MYE0", "summary": "This article provides the \"Price to sales forward\" financial metric for MaxCyte, Inc. (DUS:MYE0) on the Dusseldorf Stock Exchange, as presented on the TradingView platform. It acknowledges that the market is currently closed with no trades. The content is primarily a data point w", "url": "https://www.tradingview.com/symbols/DUS-MYE0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T00:10:59", "published_display": "12 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte(MXCT) Stock Options Chain | Quotes & News", "summary": "This article provides details on the stock options chain for MaxCyte (MXCT). It also indicates that quotes and news related to MaxCyte are available.", "url": "https://www.moomoo.com/stock/MXCT-US/options-chain?chain_id=Name1K9-3FXPhg.1kvnlg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A61,%22invite%22%3A%2270107943%22,%22promote_content%22%3A%22mm%3Afeed%3A112092721905669%22,%22f%22%3A%22www.moomoo.com%2Fstock%2FCSCO-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T08:11:39", "published_display": "09 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MaxCyte, Inc. \u2013 DUS:MYE0", "summary": "This article displays the \"Price to earnings forward\" metric for MaxCyte, Inc. (DUS:MYE0) on TradingView. It appears to be a financial data point presented without further commentary or analysis, indicating market performance data. The content primarily consists of navigation and", "url": "https://www.tradingview.com/symbols/DUS-MYE0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T06:41:03", "published_display": "09 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc focuses on cell engineering. Nasdaq-listed MXCT targets long-term growth", "summary": "MaxCyte Inc, a Nasdaq-listed life sciences company, specializes in cell engineering platforms crucial for advanced therapeutics and research. The company aims for long-term growth by expanding its technology footprint as demand for cell and gene therapies increases globally. MaxC", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/maxcyte-inc-focuses-on-cell-engineering-nasdaq-listed-mxct-targets/69724187", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T13:39:15", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MaxCyte, Inc. \u2013 NASDAQ:MXCT", "summary": "This article provides the enterprise value to EBITDA forward for MaxCyte, Inc. (NASDAQ: MXCT). It appears to be a financial data snippet from TradingView, indicating the value and any changes for the specified financial metric. The content itself seems to be a display of this sin", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:09:03", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte stock leans on platform demand. Nasdaq listing stays central.", "summary": "MaxCyte Inc. (MXCT) is a Nasdaq-listed cell-engineering company whose investment case focuses on the adoption and usage of its Flow Electroporation platform by biopharma and research customers. Without new immediate catalysts, the company's performance is tied to execution, custo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/maxcyte-stock-leans-on-platform-demand-nasdaq-listing-stays-central/69680975", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:12:13", "published_display": "03 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of MaxCyte, Inc. \u2013 NASDAQ:MXCT", "summary": "This article provides a brief snapshot of the \"Price to book forward\" metric for MaxCyte, Inc. (NASDAQ:MXCT) on TradingView. It shows the period, value, and change percentages for this financial indicator. The content is concise and focused solely on this specific financial data ", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:09:40", "published_display": "29 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MaxCyte, Inc. \u2013 LS:A2AGVE", "summary": "This article provides access to the \"Price to sales forward\" financial metric for MaxCyte, Inc. (A2AGVE) on the TradingView platform. It highlights that market data is provided by ICE Data Services and FactSet, and SEC filings by Quartr. The content mainly consists of navigation ", "url": "https://www.tradingview.com/symbols/LS-A2AGVE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:40:55", "published_display": "29 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MXCT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for MaxCyte, Inc. (MXCT) stock, based on analyst ratings and current market data. It includes information on the company's past performance, stock volatility, market capitalization, earnings, revenue, and future outlook, as well a", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:33", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MYE0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MaxCyte, Inc. (MYE0) stock, including analyst price targets, past financial performance, and key company metrics. It details the stock's highest and lowest recorded prices, upcoming earnings reports, and financial statistics such as revenue, n", "url": "https://www.tradingview.com/symbols/DUS-MYE0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:59", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT)", "summary": "This article provides an overview of MaxCyte, Inc. (NASDAQ:MXCT) stock, including its current price, performance, and analyst forecasts. It covers financial data, market capitalization, earnings reports, and technical analysis, noting that MXCT's stock has shown recent gains but ", "url": "https://www.tradingview.com/symbols/NASDAQ-MXCT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:25", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating", "summary": "Craig-Hallum has reiterated its Buy rating on MaxCyte (MXCT.US). This indicates a continued positive outlook from the firm regarding the company's stock.", "url": "https://www.moomoo.com/news/post/72030663/craig-hallum-maintains-maxcyte-mxctus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-23T20:13:17", "published_display": "23 Jun 2026 20:13", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectorBuilder Partners With MaxCyte\u00ae to Advance Clinical-Grade Cell Engineering", "summary": "VectorBuilder and MaxCyte have formed a strategic partnership to create a new gene delivery solution for ex vivo cell engineering. This collaboration integrates VectorBuilder\u2019s MiniVec\u2122 plasmid system with MaxCyte\u2019s Flow Electroporation\u00ae technology, aiming to enhance cell viabili", "url": "https://www.businesswire.com/news/home/20260623060175/en/VectorBuilder-Partners-With-MaxCyte-to-Advance-Clinical-Grade-Cell-Engineering", "source_name": "Business Wire", "published_at": "2026-06-23T13:11:57", "published_display": "23 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) grants RSUs and stock options to director", "summary": "MaxCyte (MXCT) director John Joseph Johnston was granted 30,421 restricted stock units and stock options for 49,579 shares as part of his annual non-employee director compensation. The RSUs will vest on June 17, 2027, contingent on his continued service, and the stock options hav", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-fc8a30b7d649.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:09:25", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant", "summary": "MAXCYTE director Cynthia Collins was granted 30,421 restricted stock units and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. These equity awards, made on June 17, 2026, are part of the company's Equity Grant Policy for non-employee di", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-86da2d334293.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:09:25", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 MaxCyte Inc For: 22 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing update, specifically a Form 4 for MaxCyte Inc, dated June 22. It primarily serves as a notice of the filing without providing further details on the content of the form itself. The content primarily consists of market data an", "url": "https://za.investing.com/news/stock-market-news/form-4-maxcyte-inc-for-22-june-93CH-4338578", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T22:28:00", "published_display": "22 Jun 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director receives RSUs and options in annual equity grant", "summary": "MaxCyte Inc. director Stanley C. Erck received an annual equity grant comprising 30,421 restricted stock units (RSUs) and an option to purchase 49,579 shares at $1.13 per share. The RSUs will vest on June 17, 2027, contingent on his continued service. Following this grant, Erck's", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-2151fe79724b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:25", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award", "summary": "MAXCYTE (NASDAQ: MXCT) director Douglas Richard was granted 30,421 Restricted Stock Units (RSUs) and 49,579 stock options with an exercise price of $1.13 per share. These grants are part of the company's annual equity award policy for non-employee directors, with the RSUs vesting", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-60ccfe04342d.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant", "summary": "MaxCyte (MXCT) director Brooke William W was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share. The RSUs vest on June 17, 2027, contingent on his continuous service, and the stock options expir", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-a0a54f6d3fa7.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director receives RSU and stock option grant", "summary": "MaxCyte (MXCT) director Yasir B. Al-Wakeel was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares at an exercise price of $1.13 per share. These equity awards are part of his annual non-employee director compensation package, with the shares vesting ", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-de816ac43149.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director awarded RSUs and stock options in annual grant", "summary": "MaxCyte, Inc. director Rekha Hemrajani received an annual equity grant comprising 30,421 restricted stock units (RSUs) and 49,579 stock options with a strike price of $1.13, expiring in 2036. These awards, part of the non-employee director policy, vest on June 17, 2027, contingen", "url": "https://www.stocktitan.net/sec-filings/MXCT/form-4-maxcyte-inc-insider-trading-activity-d140bab17f05.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:45", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVWdCVWkxMnc1WHRoYURZRzlQOWVuYkVFWjJqa01OOEI3SE5vaFcyR09iYXlFdGY5QzQweV9WVDJidUZDa2JQRlc2NG5yWC13OWo3YnUzV0tfVVVzQW91aE9lUkgwVkNpR3RBUDdhXzhPMmZyd2NLc3dMYkVhVVFIWHlsN0MxamNwOF9NRFVQZmJubnBhbENQWXFHb294UjdmQ1kyX0tjQUM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)", "summary": "Craig-Hallum analyst Matt Hewitt has reaffirmed a Buy rating on MaxCyte (MXCT). Despite recent negative insider sentiment, the company reported Q1 revenue of $9.65 million and a GAAP net loss of $4.75 million, with an analyst consensus of Moderate Buy and a price target of $4.00.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MXCT-Q/pressreleases/2551932/craig-hallum-reaffirms-their-buy-rating-on-maxcyte-mxct/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T10:39:23", "published_display": "19 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Stock - chart levels and volatility on a quiet news day", "summary": "MaxCyte stock traded on Nasdaq without new corporate headlines, leading analysts to focus on its chart performance, volatility, and key moving averages. The company, which develops cell-engineering technologies for biopharma partners, is in a period of consolidation. Investors ar", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/maxcyte-stock-chart-levels-and-volatility-on-a-quiet-news-day/69574749", "source_name": "AD HOC NEWS", "published_at": "2026-06-18T16:40:41", "published_display": "18 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte shareholders elect directors and approve auditor at annual meeting", "summary": "MaxCyte, Inc. announced the results of its 2026 annual meeting, where shareholders elected three Class II directors\u2014Patrick Balthrop, Cynthia Collins, and Stanley Erck\u2014and ratified CohnReznick LLP as its independent auditor for the fiscal year ending December 31, 2026. Despite th", "url": "https://www.investing.com/news/sec-filings/maxcyte-shareholders-elect-directors-and-approve-auditor-at-annual-meeting-93CH-4748661", "source_name": "Investing.com", "published_at": "2026-06-18T11:40:25", "published_display": "18 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com", "summary": "MaxCyte, Inc. held its 2026 annual meeting where shareholders elected three Class II directors\u2014Patrick Balthrop, Cynthia Collins, and Stanley Erck\u2014and ratified CohnReznick LLP as their independent auditor for the fiscal year ending December 31, 2026. Despite the stock being down ", "url": "https://ng.investing.com/news/sec-filings/maxcyte-shareholders-elect-directors-and-approve-auditor-at-annual-meeting-93CH-2564147", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T10:09:54", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc (MXCT) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE1wWV9odWNtOFdLODRVSWRQTzZzOFM4d2dwQWljNF9sWE9UdFVOTG85SVY5VS0ycWVsXzZQZFE0eWtvOXNoc3NDa08tb245WXJQQ1hTelFJVGhMUHJQdU5BTmVBdmlLeGh4N0lWQ1p5REw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:47:12+00:00", "published_display": "17 Jun 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc. (MXCT) Q1 2026 Earnings: EPS Surges Past Estimates Despite Revenue Disclosures Left Unclear - Annual Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxOX0lBMXRtQTh4QzZCUkwtRmEzbVRpc09uYW43MWNiR1ZTVHFQUC1TV2Z0dk40UTRBSHhxMWh4clRaQTA3bVVoNkR2WllkN2JmX1FLSDU1NHVDOFhaX0lVUy1xa0Z2RVZQS0lOODVRU0Q3bmR4bTEydHBSSkh2akRJYTF6YU9laDFtd0ktQ1EyMGRwdnlrZmRTYno0NzVyOWYwLWl4Z2FnNFZ1ZV9EYktMR2o4N3VmbG5FbUpzLXRRUmFUYi0xNHhiam5pOUNuQXoyVXU1NlJRZzdqUWs5ZDEzXzNn?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors", "summary": "", "url": "https://finance.yahoo.com/news/why-maxcyte-mxct-becoming-high-092702917.html", "source_name": "Insider Monkey", "published_at": "2026-05-13T09:27:02+00:00", "published_display": "13 May 2026 09:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...", "summary": "", "url": "https://finance.yahoo.com/news/maxcyte-inc-mxct-q1-2026-050148503.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:01:48+00:00", "published_display": "13 May 2026 05:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/042a4e49-e2c9-383d-8f68-731df522edbe/maxcyte-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-13T01:09:08+00:00", "published_display": "13 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/123ba984-df64-3ac7-8a5f-1121813da801/maxcyte%2C-inc.-q1-2026.html", "source_name": "Moby", "published_at": "2026-05-13T00:53:09+00:00", "published_display": "13 May 2026 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/news/maxcyte-inc-mxct-reports-q1-214004141.html", "source_name": "Zacks", "published_at": "2026-05-12T21:40:04+00:00", "published_display": "12 May 2026 21:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance", "summary": "", "url": "https://finance.yahoo.com/news/maxcyte-reports-first-quarter-2026-200500117.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte posts $4.8M loss, still lines up $10M stock buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRjZoYXE5MzlmY3VvWmJrcmdkMVl1OE1zX0M3b2c4cE95Nk1hZ043a2xOMWNnS3RxUUdpbFRBT05fdGxraFd4aVkweHpVcXExa3pBOFhRM2lhWEhxMlNob1ItZWRTbVlNeUFHZjM4WkNmcVZWVHExeFplNkRwOFNreFVhYlpNcVhuN1R0S0ljbmdPZENZTFZZeG55VDVyOFBtMkxtX2NXV2dUSGdsMjRWLV9rd3FNeVBjeXJYRlBCYno?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte Inc. (MXCT) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNSGF3clA5MTNxXzFxYTBCN1l4cDNuNFRoMFlRdmFQaGZMUkVhSVdZanJaSHdPQ3UyR1Z1Z1RENUFERmVpWkdNaUZ2bUVNaTZCaXhUZ25pWmVrZ05WREFSdXdIT2xUdmgzU1VTdFRaM0hIc3c0MjRmekhGeW5jaXhSMlVxMHJrTHk2TnRTYnpOSW5ydw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPSzR3SU53LTZEU0hiMWtqMDBGM1pjWF9YSXpBNXNPYlZEZ3dTZlJ4OTJDOV90a0dGTHFQbGx5OU5QbzlpXzFDb3RhOXA0dXdjS04wVGdaa2lDVkUtdFNMcHQ3UWRZaEJZcHkxOU9HcjVMMVU0aG5Sc0k3NjUxZ0hITUJ0YmcxcjZ5TlFhX2ZYdUh5YnR1Tnk0?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New MaxCyte lab device runs 96 cell samples in a three-minute cycle", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPTXZXWFhIdnhfZzRpLXI2S1czLU1zcHVQQ0ZVVUJYNm5jaWNIa0liUHJGc0o2dnlNekhac3podTRGc0JjRFQwVmNENUtINmRmVF9oQzNhdWtYeTAxTWxjd2ZINVZfQ18zcVhMNFlLTmFvQlpTNU9Rdkoxai1nbWtJT3N6Z3JDZFZmMGw0cEtWN3V2NlFMNTVaRlJDdEZSTHZtejRnUGtRa3pQLUJKZzhidXIyVWFFV29lNVlORmI0MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPeTFtdkhCd0ZseE96MkkwM3lNd3RrN2xnd2R1Mmc4dG5TSDR1TDJSNjJ1VjFNQUU0WkUzTnZoMkUxVWl4UGJPdEFKUWs5a18tbnZzdWQteHlncXg0dlp2amdZMzFETE5xNWpIMW9tVWIweV8zLTgzaXFVX2RVdGVNdmtZQkdzWnJBWWhpTmppbjg5NHdtTWJFdElqREFyeWQtYkk5cGpKY1ZZRzJ3SVF2RXd2Yk5uVk9S?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy MaxCyte (MXCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1aUWQ3RzRHcDVRQTdYS3dWaVNUUkFPeWNpOU9CQWVMYXFSMF9jemdHT0xzbk4tMkNicmlkczA4Xy1LVUdnTER0N21jcUJMYURKcjhFYWwydTVlSkQzeWJFNHNUYmdnaHF3Z3NxUg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-08-01T15:54:32+00:00", "published_display": "01 Aug 2021 15:54", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SUNDAY NEWSPAPER SHARE TIPS: MaxCyte and IQE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcWdDZ29zR3FUUnR3alZsUG1uUk52eG80SEU0ZG80dDlaSFhfVWJ1NXlfcGg1eVV2aTczdFgyUTBjZTMyOG02V1d0aXhBbTJObjNmcmdmWTBYemlDOThfR1lOLU9xRE8tTTBfd1l2SkN1LWdmUkJxTWlVcWhmZXBJZmZDVHQwQlExRkEtcUR4LTVfS2NnX01ndmNFUlkzSUg3TlcwbEZ5OHBQZ9IBrwFBVV95cUxNMVlrdHZ5aDFiWC1BeHN4S25YLVFVdVo0ZXpsTHI4WDhNWDQ5N0EtWF85WlQ3SjcydEFuR2YxX2xndVFQM0tLeHhDUnFvVGJxUjdFYjZIMVcyZTY3NkF1Q3VXazZDVFNNVnZ0YVZaRmhSdEptRzlmc1FGcGk1WkhGd0d5OVh4SVI1Y01Nb05JcFRpdG1NMWhKWTMyZ0RXS191T0txZXVLcmRBcEVwYXdv?oc=5", "source_name": "This is Money", "published_at": "2019-05-26T07:00:00+00:00", "published_display": "26 May 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 57, "sentiment_summary": {"positive": 8, "negative": 5, "neutral": 44, "score": 52, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 78, "events": [{"event": "earnings", "label": "Earnings", "weight": 15.34, "count": 30}, {"event": "general", "label": "Market update", "weight": 11.35, "count": 20}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 1.33, "latest_week": "2026-07-10", "one_week_move": 9.5, "four_week_move": 18.7, "twelve_week_move": 56.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.251963, "market_dynamics_buy_signal": false, "relative_strength": -11.430259, "fair_value_gap": -55.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.6129, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.5% over one week, +18.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 9}, {"label": "Moomoo", "count": 2}, {"label": "AD HOC NEWS", "count": 2}, {"label": "StockStory", "count": 2}, {"label": "The Manila Times", "count": 1}, {"label": "scanx.trade", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 30}, {"label": "Market update", "count": 20}, {"label": "Macro sensitivity", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+9.5% over one week, +18.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026"}], "updated_at": "2026-07-16T15:23:19.144318+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}